Watson Pharmaceuticals of Parsippany, N.J., and Antares Pharma. Inc. of Ewing, NJ, have announced the launch of Gelnique (oxybutynin), a transdermal gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

Gelnique is a topical, hydroalcoholic gel that is applied once-daily to the thigh, abdomen, upper arm or shoulder, delivering a consistent dose of oxybutynin through the skin over a 24-hour period. It is not metabolized by the liver as with orally-administered oxybutynin products. In a Phase 3 study, it showed a significant median reduction in urinary incontinence episodes (67%) compared to a placebo (50%) at week 12, according to a press release issued by the companies. Gelnique was approved by the FDA on Dec. 8, 2011.